ACTRN12619001032145
Not yet recruiting
Phase 3
Effect of nebulised furosemide on breathlessness and cough in interstitial lung disease: a pilot study
Hunter New England Health0 sites12 target enrollmentJuly 18, 2019
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hunter New England Health
- Enrollment
- 12
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \> 18 years
- •Confirmed physician diagnosis of an interstitial lung disease
- •Medical research council dyspnoea scale of 3\-5
- •Cough visual analogue scale \>4cm
- •FVC \>\=30% predicted
- •DLCO \>\=20% predicted
Exclusion Criteria
- •Current smoker
- •Clinical history of asthma or vocal cord dysfunction
- •Currently pregnant or breastfeeding
- •Any clinically significant cardiopulmonary abnormalities not related to ILD, including features of congestive cardiac failure on examination or history suggestive of uncontrolled ischaemic heart disease.
- •Any clinically significant neurological, renal, endocrine, gastrointestinal, hepatic or haematological abnormalities uncontrolled with standard treatment
- •History of psychiatric, medical or surgical disorders that may interfere with study
- •Clinical history suggestive of respiratory infection in month preceding study
- •Alcohol or recreational drug abuse
- •Inability to understand directions for study assessment, including inability to comprehend English language.
- •Inability to complete questionnaires required for the study, including visual analogue scales.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Compare effect of furosemide inhalation versus placebo in patients with acute cardiogenic pulmonary edemaAcute pulmonary oedema.Left ventricular failureIRCT2017101436753N1Vice chancellor for research, Iran University of Medical Sciences120
Recruiting
Phase 1
The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Advanced Respiratory Diseases (INFURO)CTIS2024-514672-41-00Fakultni Nemocnice Hradec Kralove114
Completed
Phase 3
Efficacy of nebulization salbutamol versus Efficacy of nebulization combination of salbutamol and furosemide in wheezing childHealth Condition 1: J989- Respiratory disorder, unspecifiedCTRI/2020/08/026975Government Medical College Aurangabad100
Unknown
Phase 1
Inhaled Nebulized Furosemide & Physical Activity-Related BreathlessnessBreathlessnessNCT01851980McGill University30
Recruiting
Phase 3
Evaluation of the effect of nebulised Furosemide on acute dyspneaIRCT20151003024317N12Iran University of Medical Sciences300